Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
Public ClinicalTrials.gov record NCT03313778. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone and in combination in participants with solid tumors.
Study identification
- NCT ID
- NCT03313778
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 161 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 13, 2017
- Primary completion
- Nov 20, 2027
- Completion
- Nov 20, 2027
- Last update posted
- Mar 3, 2026
2017 – 2027
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Angeles Clinic and Research Institute | Los Angeles | California | 90025 | — |
| The George Washington Cancer Center | Washington D.C. | District of Columbia | 20037 | — |
| Orlando Health Cancer Institute | Orlando | Florida | 32806 | — |
| Florida Cancer Specialists | Sarasota | Florida | 34232 | — |
| H Lee Moffitt Cancer Center and Research Institute | Tampa | Florida | 33612-9416 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| NYU Langone Medical Center | New York | New York | 10016 | — |
| The Cleveland Clinic Foundation | Cleveland | Ohio | 44195-0001 | — |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15219 | — |
| UT Southwest Medical Center | Dallas | Texas | 75390 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03313778, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 3, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03313778 live on ClinicalTrials.gov.